NEO · NASDAQ · Medical - Diagnostics & Research

NeoGenomics (NEO)

Runs cancer diagnostic laboratories serving community oncologists, pathologists, and pharmaceutical trial sponsors.

$18.64
vs last close−0.25 (−1.32%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue152156156165168172168181188190187202
Cost of revenue90889192939595104107114106110
Gross profit626865727577737780768192
8786969496961011251078799102
Research & development578888109991011
797886858786889692879091
Selling & marketing181820222022232422232427
General & administrative616066636764657270646664
Other expenses2122123207−900
Operating income−24−19−31−22−21−18−28−48−27−11−18−10
333332221−1112
Interest income555554422211
Interest expense222222211111
Other non-operating income−4−5−5−5−5−4−4−3−11−1−12
Income before tax−21−15−28−19−18−16−26−46−26−12−182
Income tax expense−3−1−100−10−11−300
Net income from continuing operations−19−14−27−19−18−15−26−45−27−10−172
Net income−19−14−27−19−18−15−26−45−27−10−172
EPS, basic−$0.75−$0.55−$1.05−$0.75−$0.70−$0.60−$1.00−$1.75−$1.05−$0.38−$0.65$0.10
EPS, diluted−$0.75−$0.55−$1.05−$0.75−$0.70−$0.60−$1.00−$1.75−$1.05−$0.38−$0.65$0.10
Weighted average shares, basic252525252525252626262626
Weighted average shares, diluted252525252525252626262626
EBITDA−25−8124−6−28−105−119
Depreciation & amortization181818181818181716161616
EBIT−20−14−26−17−16−15−24−45−26−12−173